<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04421014</url>
  </required_header>
  <id_info>
    <org_study_id>999920087</org_study_id>
    <secondary_id>20-AG-N087</secondary_id>
    <nct_id>NCT04421014</nct_id>
  </id_info>
  <brief_title>Ketone Ester Effects on Biomarkers of Brain Metabolism and Cognitive Performance in Cognitively Intact Adults 55 Years Old or Older</brief_title>
  <official_title>Ketone Ester Effects on Biomarkers of Brain Metabolism and Cognitive Performance in Cognitively Intact Adults More Than or Equal to 55 Years Old or Older. A Double-Blinded Randomized Controlled Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

      In Alzheimer s disease (AD) the brain cannot use glucose as a fuel. The brain can use ketones
      as a fuel instead of glucose. Researchers want to test a supplement, HVNM Ketone Ester (KE).
      It may improve brain metabolic function and cognition in normal people and, perhaps, down the
      road, in patients with AD.

      Objective:

      To study the change in brain ketone levels in people after 28 days of taking HVMN KE compared
      with baseline and placebo. Also, to study changes in cognitive performance.

      Eligibility:

      People 55 years old or older with metabolic syndrome and no cognitive impairment

      Design:

      Participants will have 4 visits.

      Participants will be screened at Visit 1 with:

      Medical history

      Physical exam

      Blood and urine tests

      Cognitive testing

      Participants will be randomly assigned to receive either the study supplement or a placebo
      with same amount of calories. Neither they nor the researchers will know which they receive.

      Visit 2 will include repeats of some screening tests. It will also include:

      Stool sample (brought from home)

      MRI/MRS: Participants will lie on a table that slides in and out of a scanner. A coil will be
      placed over their head. They may be asked to perform leg exercises.

      First dose of study supplement or placebo

      About 2 weeks after Visit 2, Visit 3 will include blood and urine tests and a questionnaire.

      About 2 weeks after Visit 3, Visit 4 will include repeats of the Visit 2 tests.

      Participants will drink the study supplement or placebo 3 times per day during the study.
      They will keep a daily log of each dose. They will bring the log to Visits 3 and 4.

      Participants will by contacted by phone once per week during the study to see how they are
      doing.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We hypothesize that supplementation with a ketone ester drink [HVMN Ketone Ester (KE)]
      compared to placebo, in cognitively intact adults 55 years old with Metabolic Syndrome
      (Mets), will (i) increase peripheral and brain ketone levels [primarily f3-hydroxybutyrate
      (BHB) and secondarily acetoacetate (AcAc)], (ii) improve neuronal/astrocytic insulin
      resistance (IR) and induce a change in neuronal/astrocytic metabolism as reflected on blood
      Extracellular Vesicle (EV) biomarkers, (iii) improve cognitive performance, (iv) boost
      mitochondrial function in muscle, and (v) change gut microbiome. These effects will be
      examined acutely, after single (NotEqual) dose administration, and chronically, after 28 days
      on the supplement x 3 times per day. The changes in EV biomarkers and cognition will be
      associated with the elevation of ketones in brain. The study will involve a Screening Visit
      and three additional Visits to assess acute effects, compliance and chronic effects,
      respectively.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 31, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Brain concentration of BHB using brain Magnetic Resonance Spectroscopy</measure>
    <time_frame>28 days - outcome assessed at Visit 2 (baseline measurement before the first dose and after 75 min); Visit 4 (before and after 75 min from last dose).</time_frame>
    <description>To detect with brain MRS, a significant change in the concentration of BHB, after 28 days of supplementation with the HVMN KE compared to baseline and placebo.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Metabolic Syndrome</condition>
  <condition>Normal Cognition</condition>
  <arm_group>
    <arm_group_label>HVMN Ketone Ester/ Arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>25 participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/ Arm 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>25 participants</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>HVMN Ketone Esther drink</intervention_name>
    <description>The main ingredient of HVMN Ketone Ester [(R)-3- hydroxybutyl (R)-3- hydroxybutyrate)] is regulated as GRAS (Generally Recognized as Safe) substance by the FDA (https://www.accessdata .fda.gov/ scripts/ fdcc/index.cfmset=GRASNotices&amp;amp;id=515). The HVMN KE compound is already being sold in the market as a ketogenic supplement and is especially popular among athletes, such as cyclists (sold by the official website of the company (https://hvmn.com/ketone-ester) and in a popular selling website (https://www.amazon.com/HVMN (NotEqual)Ketone-Pocket-Sized (NotEqual)Sugar-Free (NotEqual)Performance/dp/ B07CTP3XST). The dose and formulation (25 g of KE contained in 65 ml of the drink HVMN KE), daily scheme (3 times daily) and total duration (28 days) are identical to a previous safety human study.</description>
    <arm_group_label>HVMN Ketone Ester/ Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo: isocaloric dextrose drink</intervention_name>
    <description>The main content of the Placebo will be an aqueous solution containing ~ 35 g of dextrose. To better match the taste of the placebo to that of the HVMN KE, we will add a fruity flavor powder (provided by HVMN) and stevia. We will also add Denatonium Benzoate (Bittrex) to match the bitterness of HVMN KE. The placebo will be prepared and dispensed by the NIA Pharmacist.</description>
    <arm_group_label>Placebo/ Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        In order to be eligible to participate in this study, an individual must meet all of the
        following criteria:

          1. Ability to provide informed consent and willingness to sign a written informed consent
             document

          2. Male or female, age &gt;=55 years old

          3. Cognitively intact status ascertained during screening (defined as absence of
             significant memory or cognitive changes in the last 2 years by subjective report,
             Clinical Dementia Rating (CDR) of 0, and Montreal Cognitive Assessment (MoCA) &gt; 26)

          4. Ability to take oral medications

          5. Willingness to adhere to all study procedures including having MRI/MRS.

          6. Presence of Metabolic Syndrome (MetS). Specifically, they should meet three of the
             five following MetS diagnostic criteria to be eligible:

               -  Receive drug treatment for elevated triglycerides (TGs) or have serum TGs
                  &gt;=150mg/dL (1.7 mmol/L)

               -  Receive drug treatment for low HDL-cholesterol or have serum HDL-cholesterol&lt;40
                  mg/dL (1.0 mmol/L) in males; &lt;50 mg/dL (1.3 mmol/L) in females

               -  Receive drug treatment for high Blood Pressure (BP) or have BP&gt;=130/85 mmHg

               -  Receive drug treatment for high blood glucose or have fasting plasma
                  glucose&gt;=mg/dL

               -  Central obesity, defined as a waist circumference cm (40 in) in men and&gt;=88cm (35
                  in) in women.

        EXCLUSION CRITERIA:

        An individual who meets any of the following criteria will be excluded from participation
        in this study:

          1. Previously diagnosed with a condition causing clinically significant cognitive
             impairment, such as MCI, AD or other type of dementia (such as vascular dementia, Lewy
             body dementia and frontotemporal dementia).

          2. History of clinically significant brain disorders, such as stroke, multiple sclerosis,
             Parkinson s disease or other movement disorders, brain tumors, history of meningitis
             or encephalitis, history of moderate or severe traumatic brain injury (defined as
             Glasgow Coma Scale of 12 or less), epilepsy. Certain common neurological disorders not
             considered relevant (e.g. migraine, essential tremor) or incidental neuroimaging
             findings that are common and of uncertain clinical significance (e.g. mild-moderate
             microvascular changes on MRI) may be allowed.

          3. Chronic and significant psychiatric conditions (e.g. history of bipolar disorder,
             schizophrenia, PTSD, moderate to severe depression or treatment-resistant depression.
             Unipolar depression or anxiety disorder may be allowed if mild or if successfully
             treated with single anti-depressant or anti-anxiety agents.

          4. Positive urine drug screen (and no prescription medication accounting for the positive
             test).

          5. Positive HIV, HBV or HCV status during screening.

          6. Contraindications for MRI (pregnancy, pacemakers or other implanted devices, ferrous
             metal implants or shrapnel in or around the head etc.).

          7. Anemia (defined as HGB &lt; 12 for men or &lt; 11 g/dl for women)

          8. Poor venous access.

          9. Lactation or Pregnancy (positive urine pregnancy test. Pregnancy tests will not be
             done on post-menopausal women defined as one of the below criteria:

               1. prior bilateral oophorectomy

               2. Amenorrhea for 12 months or more

         10. Known severe allergic reactions to the HVMN KE or other ketogenic supplement or stevia
             products.

         11. Following high fat/low carb diet (ketogenic) diet or very low calorie (&lt;500 calories)
             diet or taking other ketogenic supplements (such as Medium Chain Triglycerides (MCTs),
             Ketone Salts) or fasting intermittently and unwilling to stop it while on the HVMN
             KE/Placebo.

         12. Very high or severe hypertriglyceridemia &gt;=886mg/dL or 10.0 mmol/L)

         13. Severe Hypertension (systolic blood pressure &gt;=180mmHg and/or diastolic blood pressure
             &gt;=120mmHg)

         14. Weight &gt;=300 lbs (MRI scanner weight limit)

         15. Diabetes Mellitus (type 1 or 2)

         16. Taking the drug metformin.

         17. Non-English speakers (given staffing constraints for cognitive testing administration
             and need for decreased variability in testing procedures for a small N study).

         18. Participant has any concurrent medical condition, so that participation in the
             clinical study would not be in her/his best interest, in the PI s judgement.

         19. To be eligible to consent for optional thigh MRI: Individuals with joint replacements
             that may be affected by the defined exercise protocol or which may prevent MRI
             analysis or any condition, in the opinion of the investigator, that would prevent
             successful completion of the exercise protocol such as, but not limited to reported
             osteoarthritis, rheumatoid arthritis and/or fibromyalgia.

        5.3 INCLUSION OF VULNERABLE PARTICIPANTS

          -  Children: No inclusion is planned. This study aims to investigate the effects of aging
             55 years old) on brain metabolism, therefore inclusion of children is inappropriate
             with respect to the purpose of the research.

          -  Pregnant Women, Fetuses, or Neonates: No inclusion is planned. We will exclude women,
             fetuses or neonates with respect to the health of participants, specifically, due to
             the risk associated with the MRI procedure and the unknown effects of the ketone ester
             supplement.

          -  Prisoners: No inclusion is planned. This study involves several visits to the NIA
             Clinical Unit, which prisoners are unable to perform. Therefore, inclusion of
             prisoners is inappropriate with respect to the purpose of the research.

          -  Decisionally Impaired Adults: No inclusion is planned. Cognitive intact status will be
             ascertained at baseline based on Clinical Dementia Rating (CDR) of 0, and Montreal
             Cognitive Assessment (MoCA) &gt; 26, since the main objective of the study is to study a
             population of cognitively intact individuals. Therefore, inclusion of decisionally
             impaired adults is inappropriate with respect to the purpose of the research.
             Moreover, participants are not expected to become decisionally impaired over the
             course of the study.

          -  NIH Employees: We intend to include NIH staff (to include NIH contractors and special
             volunteers, guest researchers and trainees) in this study. The staff will be invited
             to participate through standard recruitment efforts. Participation will be voluntary
             and neither participation nor refusal to participate will have an effect, either
             beneficial or adverse, on the participant s employment or position at NIH. We will
             follow the Guidelines for the Inclusion of Employees in NIH Research Studies and will
             give each employee a copy of the NIH information sheet on Staff Research Participation
             per NIH OHSRP SOP 14F.4: Research Involving NIH Staff as Subjects.

          -  Neither participation nor refusal to participate will have an effect, either
             beneficial or adverse, on the participant s employment or work situation.

          -  The NIH information sheet regarding NIH employee research participation will be
             distributed to all potential subjects who are NIH employees.

          -  The employee subject s privacy and confidentiality will be preserved in accordance
             with NIH Intramural policies, which define the scope and limitations of the
             protections.

          -  Subjects that are employees/staff will be consented in the usual manner. The inclusion
             of employees or staff is not anticipated to affect the research outcome; therefore, if
             the subject is a co-worker (including a supervisor, subordinate or coworker) the
             subject may be consented by another co-worker and/or subordinate.The study PI will not
             be involved in the consenting of employees or staff.

          -  Other vulnerable populations: No inclusion is planned.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dimitrios I Kapogiannis, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute on Aging (NIA)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dimitrios I Kapogiannis, M.D.</last_name>
    <phone>(410) 350-3953</phone>
    <email>kapogiannisd@mail.nih.gov</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Institute of Aging, Clinical Research Unit</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dimitrios Kapogiannis, M.D.</last_name>
      <phone>410-350-3953</phone>
      <email>kapogiannisd@mail.nih.gov</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Fortier M, Castellano CA, Croteau E, Langlois F, Bocti C, St-Pierre V, Vandenberghe C, Bernier M, Roy M, Descoteaux M, Whittingstall K, Lepage M, Turcotte Ã‰E, Fulop T, Cunnane SC. A ketogenic drink improves brain energy and some measures of cognition in mild cognitive impairment. Alzheimers Dement. 2019 May;15(5):625-634. doi: 10.1016/j.jalz.2018.12.017. Epub 2019 Apr 23.</citation>
    <PMID>31027873</PMID>
  </reference>
  <reference>
    <citation>Soto-Mota A, Vansant H, Evans RD, Clarke K. Safety and tolerability of sustained exogenous ketosis using ketone monoester drinks for 28 days in healthy adults. Regul Toxicol Pharmacol. 2019 Dec;109:104506. doi: 10.1016/j.yrtph.2019.104506. Epub 2019 Oct 23.</citation>
    <PMID>31655093</PMID>
  </reference>
  <reference>
    <citation>Cunnane SC, Courchesne-Loyer A, Vandenberghe C, St-Pierre V, Fortier M, Hennebelle M, Croteau E, Bocti C, Fulop T, Castellano CA. Can Ketones Help Rescue Brain Fuel Supply in Later Life? Implications for Cognitive Health during Aging and the Treatment of Alzheimer's Disease. Front Mol Neurosci. 2016 Jul 8;9:53. doi: 10.3389/fnmol.2016.00053. eCollection 2016.</citation>
    <PMID>27458340</PMID>
  </reference>
  <verification_date>May 27, 2020</verification_date>
  <study_first_submitted>June 5, 2020</study_first_submitted>
  <study_first_submitted_qc>June 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2020</study_first_posted>
  <last_update_submitted>July 25, 2020</last_update_submitted>
  <last_update_submitted_qc>July 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ketogenic</keyword>
  <keyword>Brain Metabolism</keyword>
  <keyword>BETA-HYDROXYBUTYRATE</keyword>
  <keyword>Dietary Supplement</keyword>
  <keyword>Alzheimer's Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

